CLINICAL UTILITY GENE CARD

Clinical utility gene card for: Cantú syndrome

Edwin P Kirk^{*,1,2}, Ingrid Scurr³, Gijs van Haaften⁴, Mieke M van Haelst^{5,6}, Colin G Nichols⁷,
 Maggie Williams⁸, Sarah F Smithson³ and Dorothy K Grange⁹

European Journal of Human Genetics (2017) **25**, doi:10.1038/ejhg.2016.185; published online 4 January 2017

1. DISEASE CHARACTERISTICS

1.1 Name of the Disease (synonyms)

Cantú syndrome (Hypertrichotic osteochondrodysplasia).

1.2 OMIM# of the Disease

239850.

1.3 Name of the Analysed Genes or DNA/Chromosome Segments

ABCC9 at 12p12.1; *KCNJ8* also at 12p12.1.

1.4 OMIM# of the Genes

ABCC9 – *601439.

KCNJ8 – *600935.

1.5 Mutational spectrum

All reported variants to date are heterozygous single-nucleotide variants which are predicted to have an activating effect on the function of ATP-sensitive potassium channels generated by the SUR2 and Kir6.1 proteins encoded by *ABCC9* and *KCNJ8*. At least 15 different variants in *ABCC9* and two variants in *KCNJ8* have been reported to date^{1–4} (list of variants available in the GeneReviews entry for Cantú syndrome;⁵ see also the LOVD database for *ABCC9* at <http://databases.lovd.nl/shared/genes/ABCC9>). Variants in *ABCC9* to date cluster in transmembrane domain 2, with ~80% of reported patients having variants in this domain. Recurrent *ABCC9* variants affecting the amino acid residues p.Arg1116 and p.Arg1154 have been identified in approximately half of the individuals in whom pathogenic variants have been found to date. Copy number variants (small or large scale) have not been associated with Cantú syndrome.

1.6 Analytical methods

Sequencing of all coding exons and intron-exon boundaries of *ABCC9* by Sanger sequencing, as part of a targeted gene panel for Mendelian syndromes, or by exome or whole genome sequencing. Sequencing of *KCNJ8* by Sanger sequencing as a second line test, or concurrently with sequencing of *ABCC9* as part of panel, exome or genome sequencing.

1.7 Analytical validation

Sanger sequencing is predicted to detect >99% of variants in the targeted regions of the two known genes. For other sequencing

methods, sensitivity will depend on the characteristics of the test, including coverage of the coding regions and intron-exon boundaries, read depth and sequencing quality.

1.8 Estimated frequency of the disease

Incidence at birth ('birth prevalence') or population prevalence. If known to be variable between ethnic groups, please report):

Unknown. There is no known variation in incidence or prevalence among ethnic groups.

1.9 Diagnostic setting

	Yes	No
A. (Differential) diagnostics	☒	☐
B. Predictive testing	☐	☒
C. Risk assessment in relatives	☒	☐
D. Prenatal	☒	☐

Comment: Testing is useful for confirming or making the diagnosis of Cantú syndrome in an affected individual. Testing of relatives allows assessment of reproductive risks – for example, in the parents of an affected child. Prenatal diagnosis is an option where one parent is affected and a pathogenic variant has been identified. Targeted non-invasive prenatal diagnosis (NIPD) is an emerging option for families in which the father is affected. NIPD may be possible where a previous affected child has a *de novo* variant, but the suitability of this will depend on the healthcare setting.

2. TEST CHARACTERISTICS

Genotype or disease		A: True positives	C: False negative
		B: False positives	D: True negative
	Present	Absent	
Test			
Positive	A	B	Sensitivity: A/(A+C) Specificity: D/(D+B)
Negative	C	D	Positive predictive value: A/(A+B) Negative predictive value: D/(C+D)

¹Dept of Medical Genetics, Sydney Children's Hospital, Randwick NSW, Australia; ²School of Women's and Children's Health, University of New South Wales, Randwick NSW, Australia; ³Department of Clinical Genetics, St Michael's Hospital, Bristol, UK; ⁴Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands; ⁵Department of Clinical Genetics, Amsterdam Medical Center, University of Amsterdam, Amsterdam, The Netherlands; ⁶Department of Clinical Genetics, VU Medical Center, VU University Amsterdam, Amsterdam, The Netherlands; ⁷Center for the Investigation of Membrane Excitability Diseases, Washington University School of Medicine, St. Louis, MO, USA; ⁸Bristol Genetics Laboratory, Southmead Hospital, North Bristol NHS Trust, Bristol, UK; ⁹Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA

*Correspondence: Dr EP Kirk, Dept of Medical Genetics, Sydney Children's Hospital, School of Women's and Children's Health, University of New South Wales, High St, Randwick NSW 2031, Australia. Tel: +61 2 9382 1704; Fax: +61 2 9382 1711; E-mail: e.kirk@unsw.edu.au

Received 3 July 2016; revised 25 October 2016; accepted 22 November 2016; published online 4 January 2017

2.1 Analytical sensitivity**(proportion of positive tests if the genotype is present)**

Nearly 100%.

2.2 Analytical specificity**(proportion of negative tests if the genotype is not present)**

Nearly 100%.

2.3 Clinical sensitivity**(proportion of positive tests if the disease is present)**

The sensitivity of a clinical diagnosis can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.

Of 30 patients with a clinical diagnosis of Cantú syndrome included in two papers,^{1,2} 28 had variants identified in *ABCC9*. One of the two with no identified variant was subsequently found to have a different disorder, with a duplication of the 17q24.2-q24.3 region. This suggests that the clinical sensitivity of testing for variants in *ABCC9* is >95%; addition of *KCNJ8* sequencing would be expected to improve this to close to 100%. However, this assumes accurate clinical phenotyping. Depending on the specific features in an affected individual, there are a number of disorders which can present with similar features. In addition to 17q24.2-q24.3 copy number variants, these include lysosomal storage disorders, Beckwith-Wiedemann syndrome, endocrine disorders such as congenital hypothyroidism and acromegaly, Wiedemann-Steiner syndrome, Zimmerman-Laband and Temple-Baraitser syndromes and Berardinelli-Seip congenital lipodystrophy. Treatment with minoxidil can also produce very similar clinical features.⁶ The clinical sensitivity of testing will depend at least in part on the extent to which alternative diagnoses have been excluded, on clinical grounds or by specific testing, prior to testing for variants in *ABCC9* and *KCNJ8*.

2.4 Clinical specificity**(proportion of negative tests if the disease is not present)**

The specificity of a clinical diagnosis can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.

If the disease is not present, no pathogenic variants should be found in either *ABCC9* or *KCNJ8*, and thus clinical specificity should be 100%.

2.5 Positive clinical predictive value**(life-time risk of developing the disease if the test is positive)**

Clinical features are usually present from childhood. Thus, positive clinical predictive value is mainly relevant in the context of prenatal diagnosis, in the setting of a known familial pathogenic variant. In that setting, positive clinical predictive value is likely to be close to 100%, with only the small risk of laboratory error or misinterpretation of a variant as pathogenic likely to lead to a genotype-positive fetus being clinically unaffected at birth.

2.6 Negative clinical predictive value**(probability not to develop the disease if the test is negative)**

Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested:

100% if there is a proven pathogenic variant in the index case.

Index case in that family had not been tested:

This depends on whether the clinical diagnosis in the proband is correct. If a confident clinical diagnosis has been made in the proband, negative clinical predictive value would be expected to be high (but difficult to quantify) in this scenario as well.

3. CLINICAL UTILITY

3.1 (Differential) diagnostics: The tested person is clinically affected
(to be answered if in 1.9 'A' was marked)

3.1.1 Can a diagnosis be made other than through a genetic test?

No	☐ (continue with 3.1.4)
Yes	☒
	Clinically ☒
	Imaging ☒
	Endoscopy ☐
	Biochemistry ☐
	Electrophysiology ☐
	Other (please describe)

3.1.2 Describe the burden of alternative diagnostic methods to the patient

The diagnosis of Cantú syndrome can be made on clinical grounds alone (hypertrichosis, distinctive facial features and the presence of other common features such as polyhydramnios and large birth-weight).⁷ However, diagnostic imaging can make a contribution to the diagnosis. This may include skeletal survey looking for the variable mild osteochondrodysplasia, as well as cardiomegaly. The burden of this to the patient relates mainly to radiation exposure. Echocardiography may also be useful. Patent ductus arteriosus is common. There may be cardiac enlargement, with high cardiac output probably due to reduced peripheral vascular resistance (not a cardiomyopathy, although the heart is often enlarged).⁸ Blood pressure measurement (standing and prone) may be helpful. Pericardial effusion has also been observed, and some patients have pulmonary hypertension. Biochemistry is not diagnostic, but investigations such as urinary glycosaminoglycans and leucocyte enzymology for storage disorders may be helpful in excluding differential diagnoses (also low burden to the patient). Similarly, chromosome microarray could be considered to exclude 17q24.2-q24.3 copy number variants. Echocardiography, biochemistry and microarray testing all have a low burden for the patient.

3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?

The investigations described above are relatively inexpensive individually. If there is strong clinical suspicion of Cantú syndrome, the combined expense of radiological investigations, biochemical testing and chromosome microarray are comparable to or exceed the cost of proceeding directly to sequencing of *ABCC9/KCNJ8*. However, echocardiography is indicated even in a patient with a confirmed diagnosis, because it is required for clinical management.

3.1.4 Will disease management be influenced by the result of a genetic test?

No	☐	
Yes	☒	
	Therapy (please describe)	Currently there are no specific therapies for Cantú syndrome, although the possibility of therapy based on sulfonylurea drugs (for example, as a topical application

Prognosis (please describe)	for hypertrichosis) is under investigation (http://www.erare.eu/financed-projects/cantutreat). Although the diagnosis of Cantú syndrome has been made in a number of adults, the long term prognosis is currently unknown and is likely to vary depending on the specific features in individual patients. The majority of affected individuals do not have clinical features which are likely to shorten life expectancy.
Management (please describe)	The diagnosis of Cantú syndrome in an individual has important implications for management. At all ages, monitoring for cardiac complications is important in affected individuals. An understanding of the underlying pathophysiology of the common cardiovascular features is needed to prevent inappropriate management which may be harmful. Affected individuals have reduced peripheral vascular resistance, ⁸ which in many leads to cardiac enlargement with a high-output state. This is not a cardiomyopathy and should not be treated as such. Medications which further lower peripheral vascular resistance, such as calcium channel blockers, should probably not be used. Although most affected individuals have normal intellect, mild learning disabilities and particularly early motor delay have been observed. Knowledge of the diagnosis should prompt developmental evaluation in affected children and early intervention, if appropriate, to optimize developmental outcomes. Management of hypertrichosis involves standard techniques for hair removal, including laser hair removal, although the severity of the hypertrichosis may limit the effectiveness of such measures. For some affected individuals, the psychological impact of features of the condition, including hypertrichosis, the characteristic facial features and lymphedema is severe enough that psychological support may be of benefit. A mild immune deficiency has been reported, ⁷ with recurrent infections out of proportion to mildly reduced immunoglobulin levels, which may respond to intravenous immunoglobulin.

3.2 Predictive Setting: The tested person is clinically unaffected but carries an increased risk based on family history

(To be answered if in 1.9 'B' was marked)

3.2.1 Will the result of a genetic test influence lifestyle and prevention?

If the test result is **positive** (please describe)

Yes, see 3.1.4.

If the test result is **negative** (please describe)

Depends on clinical manifestations in the individual who has been tested.

3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no test has been done (please describe)?

There are no specific options in relation to this disorder.

3.3 Genetic risk assessment in family members of a diseased person

(To be answered if in 1.9 'C' was marked)

3.3.1 Does the result of a genetic test resolve the genetic situation in that family?

Yes—if a pathogenic variant is identified in the proband, testing can be offered to other family members as appropriate. Risks to offspring of

family members can be accurately assessed and options such as prenatal diagnosis offered.

3.3.2 Can a genetic test in the index patient save genetic or other tests in family members?

Clinical features can be highly variable. In particular, hypertrichosis may be much less prominent in fair-haired individuals. Testing of a mildly affected family member in whom the diagnosis is in doubt may confirm or exclude the diagnosis, making additional investigations (as discussed in 3.1.2) unnecessary. In the proband, if there is early suspicion of the diagnosis, extensive investigations for alternative diagnoses (such as skeletal survey, testing for storage disorders and endocrine testing for hypertrichosis) may be obviated by confirmation of the diagnosis of Cantú syndrome.

3.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family member?

Penetrance appears to be close to 100%, so this situation is unlikely to arise.

3.4 Prenatal diagnosis

(To be answered if in 1.9 'D' was marked)

3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis?

Yes. Children of affected individuals are at 1 in 2 risk of being affected. The risk to sibs where parents are unaffected is low, but recurrences have been reported in this setting,⁹ presumably due to somatic or germline mosaicism. In either case, prenatal diagnosis using molecular testing is enabled by a positive genetic test result in the index patient. Targeted non-invasive prenatal diagnosis could also be used in the case of a *de novo* variant or when the father is affected.

4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING

Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)

The main application of testing (other than the medical issues discussed in 3.1.4) is for reproductive purposes. In addition to the option of prenatal diagnosis (see 3.4.1) identification of a pathogenic variant in an adult makes it possible to consider preimplantation genetic diagnosis.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by EuroGentest2 (Unit 2: 'Genetic testing as part of health care'), a Coordination Action under FP7 (Grant Agreement Number 261469) and the European Society of Human Genetics, 6th Joint call for European Research Projects on Rare Diseases (JTC 2014, project CantuTreat), and by a grant from the Children's Discovery Institute at Washington University (CH-MI-II-2015-488).

1 Harakalova M, van Harsseel JJT, Terhal PA *et al* Dominant missense mutations in *ABCC9* cause Cantú syndrome. *Nat Genet* 2012; **44**: 793–796.

2 van Bon BWM, Gilissen C, Grange DK *et al* Cantú Syndrome is Caused by Mutations in *ABCC9*. *Am J Hum Genet* 2012; **90**: 1094–1101.

3 Brownstein CA, Towne MC, Luquette LJ *et al* Mutation of *KCNJ8* in a patient with Cantú syndrome with unique vascular abnormalities – Support for the role of K(ATP) channels in this condition. *Eur J Hum Genet* 2013; **S6**: 678–682.

- 4 Cooper PE, Reutter H, Woelfle J *et al* Cantú Syndrome Resulting from Activating Mutation in the *KCNJ8* Gene. *Hum Mutat* 2014; **35**: 809–813.
- 5 Grange DK, Nichols CG, Singh GK. Cantú syndrome and related disorders. In: Pagon RA, Adam MP, Ardinger HH *et al* (eds): *GeneReviews [Internet]*. Seattle (WA): University of Washington, Seattle, 2014; 1993–2016. Available from <https://www.ncbi.nlm.nih.gov/books/NBK246980/>.
- 6 Nguyen KH, Marks JG: Pseudoacromegaly induced by the long-term use of minoxidil. *J Am Acad Derm* 2003; **48**: 962–965.
- 7 Scurr I, Wilson L, Lees M *et al* Cantú Syndrome: Report of Nine New Cases and Expansion of the Clinical Phenotype. *Am J Med Genet* 2011; **155**: 508–518.
- 8 Levin MD, Singh GK, Zhang HX *et al* KATP channel gain-of-function leads to increased myocardial L-type Ca²⁺ current and contractility in Cantu syndrome. *Proc Natl Acad Sci USA* 2016; **113**: 6773–6778.
- 9 Cantú JM, García-Cruz D, Sánchez-Corona J, Hernández A, Nazaré Z: A Distinct Osteochondrodysplasia with Hypertrichosis – Individualization of a Probable Autosomal Recessive Entity. *Hum Genet* 1982; **60**: 36–41.